DCM
NGNE icon

Driehaus Capital Management’s Neurogene NGNE Stock Holding History

Driehaus Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51M Buy
143,528
+110,763
+338% +$3.05M 0.03% 293
2026
Q1 		$661K Hold
32,765
– – ﹤0.01% 328
2025
Q4 		$675K Hold
32,765
– – ﹤0.01% 363
2025
Q3 		$568K Hold
32,765
– – ﹤0.01% 398
2025
Q2 		$490K Hold
32,765
– – ﹤0.01% 388
2025
Q1 		$384K Hold
32,765
– – ﹤0.01% 377
2024
Q4 		$749K Sell
32,765
-69,422
-68% -$2.58M 0.01% 340
2024
Q3 		$4.29M Hold
102,187
– – 0.04% 286
2024
Q2 		$3.72M Buy
102,187
+56,533
+124% +$1.99M 0.04% 272
2024
Q1 		$2.32M Buy
+45,654
New +$1.52M 0.02% 301
2019
Q4 		– Sell
-2,500
Closed -$143K – 549
2019
Q3 		$143K Buy
+2,500
New +$153K ﹤0.01% 477
2015
Q3 		– Sell
-8,215
Closed -$1.14M – 591
2015
Q2 		$1.14M Sell
8,215
-2,057
-20% -$313K 0.04% 404
2015
Q1 		$1.76M Sell
10,272
-2,195
-18% -$446K 0.06% 348
2014
Q4 		$1.87M Sell
12,467
-4,512
-27% -$643K 0.08% 323
2014
Q3 		$2.26M Buy
16,979
+372
+2% +$56.7K 0.09% 293
2014
Q2 		$3.11M Sell
16,607
-8,923
-35% -$1.72M 0.1% 275
2014
Q1 		$6.5M Buy
+25,530
New +$6.56M 0.2% 138

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Driehaus Capital Management's NGNE Position: Q2 2026 in Review

Driehaus Capital Management increased its Neurogene (NGNE) stake by 338% in Q2 2026, buying an estimated $3.05M and bringing the position to 143,528 shares worth $4.51M. The position accounts for 0.03% of the portfolio, ranked #293.

Driehaus Capital Management first reported a position in NGNE in Q1 2014 and has held it in 17 quarters since. The position peaked at $6.5M in Q1 2014. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Driehaus Capital Management held 143,528 shares of Neurogene worth $4.51M as of Q2 2026.
  • Driehaus Capital Management bought 110,763 Neurogene shares in Q2 2026, an estimated $3.05M.
  • Neurogene made up 0.03% of Driehaus Capital Management's portfolio in Q2 2026, its #293 holding.
  • Driehaus Capital Management first reported a position in Neurogene in Q1 2014 and has held it in 17 quarters since.
  • Driehaus Capital Management's Neurogene position peaked at $6.5M in Q1 2014.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.